Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluconazole Effect on Famitinib PK in Healthy Subjects
NCT05147727Phase 1Completed
- Sponsor
- Hengrui
- Start
- Mar 2022
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of famitinib in solid tumor, sponsored by Hengrui. Primary endpoints: Maximum observed serum concentration for famitinib, Area under the concentration-time curve from time zero to time t for famitinib and 1 more. Started Mar 2022; status: completed.
02
Drugs
famitinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05147727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05147727.